Exelixis
From Kidney Cancer Resource
Contents |
Overview
To view the corporate site Click Here
To Contact:
Exelixis Inc.,
210 East Grand Avenue
P.O. Box 511
So. San Francisco, CA 94083-0511
(650) 837-7000 phone
(650) 837-8300 fax
George SCANGOS of Exelixis
Articles
25-Oct-2007 - Exelixis presents encouraging data for renal cancer drug
Exelixis presents encouraging data for renal cancer drug
By Staff Writer
Biotechnology company Exelixis has reported encouraging results from an ongoing multi-center open-label Phase II trial of XL880, an inhibitor of MET and VEGFR2 kinases, in patients with papillary renal cell carcinoma.
The data shows that significant majority of patients on study have experienced tumor shrinkage with prolonged duration of stable disease, highlight the potential utility of drug and its potent effects in modulating both MET and VEGFR2 in the clinical setting.
Of 19 patients with measurable disease evaluable for tumor responses, 15 (79%) have had a decrease in tumor size (4-33%), including one patient with a partial response. All 19 evaluable patients with at least one post-baseline tumor assessment have had stable disease for at least three months, including 12 patients with stable disease for six months to 15+ months. Results of preliminary analyses of plasma biomarkers and tumor samples are consistent with inhibition of angiogenesis and proliferation and an increase in apoptosis.
Preliminary pharmacodynamic analyses in 11 patients show statistically significant changes in PIGF, VEGF-A, sVEGFR2 and EPO, markers of anti-angiogenic activity, following administration of inhibitor of MET and VEGFR2 kinases (XL880). XL880 also demonstrated growth inhibition and induction of apoptosis comparing pre- and post-XL880 tumor biopsies from one patient. Preliminary pharmacokinetic analyses were consistent with results from the Phase I trial.
Michael Morrissey, Exelixis's president of R&D, said: "The Phase II trial of XL880 in PRC was supported both by the biology of the disease, which frequently is associated with activating mutations or amplifications in MET, and the favorable responses observed in patients with PRC in the reported Phase I study of the compound. We are excited about the potential therapeutic utility of modulating these targets in a variety of solid tumor types."
To view the original of this article Click Here
Disclaimer
Kidney Cancer Resource (KCR) is not influenced by sponsors. The information contained herein is not intended as a substitute for the advice of an appropriately qualified and licensed physician or other licensed health care provider. The information provided here is for educational and information purposes only. Early accurate Diagnosis (Dx.) saves lives. Please check with a physician if you suspect you are ill, never ignore Symptoms. To help your health care specialist make an accurate Diagnosis please keep notes of dates, times and details of your Symptoms. We are not offering medical advice nor do we consider links, individuals or articles accessed through this site to be offering medical advice.
E&OE - Errors & Omissions Excepted
As much of the information posted on this Web Site for peoples convenience is of a medical or technical nature, and may be a matter of life or death the E&OE is a Disclaimer showing that to the best of our ability information is accurate and correctly written or transcribed. Before acting on information on this site you are responsible for checking it with your relevant medical team. We can not be held responsible for any Errors & Omissions made; nor for information on links and articles provided in good faith.
